Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus WYAMYCIN S.
E.E.S. 200 vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic